IE
TRDA icon

Israel Englander’s Entrada Therapeutics TRDA Stock Holding History

Israel Englander’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.62M Buy
763,959
+244,603
+47% +$2.35M ﹤0.01% 2880
2026
Q1 		$6.55M Buy
519,356
+21,661
+4% +$248K ﹤0.01% 2628
2025
Q4 		$5.12M Sell
497,695
-338,914
-41% -$2.86M ﹤0.01% 2986
2025
Q3 		$4.85M Buy
836,609
+666,287
+391% +$3.9M ﹤0.01% 3187
2025
Q2 		$1.14M Buy
+170,322
New +$1.37M ﹤0.01% 4307
2025
Q1 		– Sell
-12,527
Closed -$217K – 6403
2024
Q4 		$217K Sell
12,527
-98,416
-89% -$1.78M ﹤0.01% 5265
2024
Q3 		$1.77M Sell
110,943
-36,363
-25% -$573K ﹤0.01% 3807
2024
Q2 		$2.1M Buy
147,306
+75,360
+105% +$1.07M ﹤0.01% 3503
2024
Q1 		$1.02M Buy
71,946
+47,979
+200% +$678K ﹤0.01% 4276
2023
Q4 		$362K Buy
+23,967
New +$355K ﹤0.01% 4845
2023
Q3 		– Sell
-18,298
Closed -$277K – 6573
2023
Q2 		$277K Sell
18,298
-178,955
-91% -$2.47M ﹤0.01% 4941
2023
Q1 		$2.86M Buy
197,253
+157,359
+394% +$2.1M ﹤0.01% 3089
2022
Q4 		$539K Buy
+39,894
New +$699K ﹤0.01% 4691
2022
Q3 		– Sell
-76,498
Closed -$932K – 7503
2022
Q2 		$932K Buy
+76,498
New +$580K ﹤0.01% 4424
2022
Q1 		– Sell
-46,504
Closed -$796K – 7497
2021
Q4 		$796K Buy
+46,504
New +$1.13M ﹤0.01% 4625

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's TRDA Position: Q2 2026 in Review

Israel Englander increased its Entrada Therapeutics (TRDA) stake by 47% in Q2 2026, buying an estimated $2.35M and bringing the position to 763,959 shares worth $5.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Israel Englander first reported a position in TRDA in Q4 2021 and has held it in 15 quarters since. The position peaked at $6.55M in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Israel Englander held 763,959 shares of Entrada Therapeutics worth $5.62M as of Q2 2026.
  • Israel Englander bought 244,603 Entrada Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Entrada Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2880 holding.
  • Israel Englander first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Israel Englander's Entrada Therapeutics position peaked at $6.55M in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.